Quick Answer
GALECTIN THERAPEUTICS INC reported Research And Development Expense of $14.29 million for the year ending 2025.
- GALECTIN THERAPEUTICS INC showed a decrease of -60.9% in Research And Development Expense from 2024 to 2025.
- This data is from GALECTIN THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), GALECTIN THERAPEUTICS INC's Research And Development Expense has grown by 1,240.5%.
- Historical annual values: Fiscal year 2025: $14.29 million | Fiscal year 2024: $36.57 million | Fiscal year 2023: $32.13 million | Fiscal year 2022: $31.74 million | Fiscal year 2021: $23.82 million | Fiscal year 2020: $17.98 million | Fiscal year 2019: $7.47 million | Fiscal year 2018: $6.47 million | Fiscal year 2017: $11.72 million | Fiscal year 2016: $15.33 million | Fiscal year 2015: $13.11 million | Fiscal year 2014: $8.43 million | Fiscal year 2013: $5.69 million | Fiscal year 2012: $4.53 million | Fiscal year 2011: $3.55 million | Fiscal year 2010: $1.07 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: